(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of 1.88% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Nurix Therapeutics's revenue in 2025 is $88,381,000.On average, 9 Wall Street analysts forecast NRIX's revenue for 2025 to be $5,757,553,824, with the lowest NRIX revenue forecast at $4,584,744,269, and the highest NRIX revenue forecast at $7,225,228,541. On average, 8 Wall Street analysts forecast NRIX's revenue for 2026 to be $5,929,106,176, with the lowest NRIX revenue forecast at $2,293,480,650, and the highest NRIX revenue forecast at $16,146,103,776.
In 2027, NRIX is forecast to generate $7,486,150,190 in revenue, with the lowest revenue forecast at $4,969,208,075 and the highest revenue forecast at $16,348,694,567.